Introduction
Hepatocellular carcinoma (HCC) remains the third most common malignancy in the world due to the increased incidence of nonalcoholic fatty liver disease and the high infection rate of hepatitis virus. The prognosis of HCC depends on tumor expansion. 1 One of the few opportunities for patients with HCC to achieve a cure is surgical resection. 2, 3 However, it is well known that HCC recurrence after hepatectomy is a major risk factor that affects survival. 4 A proportion of patients with HCC experience HCC
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Zhang et al recurrence after complete HCC resection. [4] [5] [6] Therefore, HCC recurrence is a main clinical challenge of HCC treatment. An accurate prediction system for patients with HCC is needed, since the choice of HCC treatment strategy is very important.
Identifying patients with high or low risks of recurrence after hepatectomy for HCC will help determine other therapy and management strategies. 7, 8 Recently, several prognostic staging systems have been reported, such as the Japanese General Stage score, the cancer of the liver Italian program (CLIP) score, and the Barcelona Clinical Liver Cancer staging system. [9] [10] [11] [12] Although these staging systems help divide patients into different groups with different outcomes, they are not suitable for use in predicting recurrence after HCC resection. Therefore, an accurate model is needed to predict the likelihood of HCC recurrence after curative resection.
Although some clinicopathological data, such as tumor multiplicity and serum α-fetoprotein (AFP) levels, have been established as poor prognostic indicators and risk factors for HCC recurrence, [13] [14] [15] [16] such clinicopathological data have limited prognostic value when used alone. Combining indicators provides an effective method for improving the prognostic value. Therefore, the objective of this study was to construct an equation for distinguishing the risk of recurrence based on routine markers in patients with HCC who had undergone an HCC curative resection.
Patients and methods Patients
A total of 804 patients with HCC who underwent curative resection at the Sun Yat-sen University Cancer Center were included in this study. The inclusion criteria were as follows: 1) pathological diagnosis of HCC (by an experienced pathologist), 2) patients with complete clinicopathological and follow-up data, and 3) patients who did not receive any chemotherapy or radiotherapy prior to the surgery. The study protocol was approved by the Clinical Research Ethics Committee of the Sun Yat-sen University Cancer Center. All procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation and with the Declaration of Helsinki (1975) , as revised in 2008. Written informed consent was obtained from all patients prior to inclusion in this study.
Demographic and clinicopathological data collection
Demographic and clinicopathological data, including age, sex, hepatitis B surface antigen (HBsAg), serum AFP level, liver cirrhosis nodule, tumor size, tumor multiplicity, tumor encapsulation, tumor differentiation, TNM stage, and microvascular invasion, were collected. The TNM stage in this study was defined according to the American Joint Committee on Cancer TNM Staging for Liver Tumors as follows: 17 primary tumor (T): (TX) Primary tumor cannot be assessed; (T0) no evidence of primary tumor; (T1) solitary tumor without vascular invasion; (T2) solitary tumor with vascular invasion or multiple tumors less than 5 cm in size; (T3a) multiple tumors more than 5 cm in size; (T3b) single tumor or multiple tumors of any size, involving a major branch of the portal vein or hepatic vein; and (T4) tumor(s) with direct invasion of adjacent organs, other than the gallbladder, or with perforation of visceral peritoneum. Regional lymph nodes (N): (NX) regional lymph nodes cannot be assessed; (N0) no regional lymph node metastasis and (N1) regional lymph node metastasis. Distant metastasis (M): (M0) no distant metastasis and (M1) distant metastasis.
Follow-up
After receiving curative hepatectomies, patients with HCC underwent follow-ups and received serological and imaging examinations, including serum AFP level analysis, abdomen ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), once every 1-6 months. For patients without evidence of an event, the last follow-up date was obtained from the medical record.
statistical analyses
Statistical analyses were performed using SPSS (version 16.0, SPSS Inc., Chicago, IL, USA). A Student's t-test and Pearson's chi-squared test, or Fisher's exact test, were chosen for examining the correlations between HCC recurrence and clinical and pathological variables. Survival curves were constructed using the Kaplan-Meier method (log-rank test). A logistic regression was performed to construct the recurrence prediction equation. A multivariate Cox proportional hazards regression model was used to evaluate the independence of the equation in predicting outcomes. Differences with P-values less than 0.05 were defined as significant.
Results
associations between clinical features and hCC recurrence
The associations between HCC recurrence and clinical features are shown in 
Performance of the hCC recurrence equation in patient prognosis
To determine the prognostic impact of the equation on patients with HCC, we conducted a Kaplan-Meier survival analysis using data from the 804 patients with HCC who were enrolled in this study. Based on the mean equation values, Univariate and multivariate Cox analyses of hCC prognostic variables 
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a model predicts hCC recurrence (P=0.007), vascular invasion (P<0.001), involucrum (P=0.01), and equation value (P<0.001) were found to be independent prognostic variables for HCC recurrence (Table 5) . Figure 3 .
Discussion
In this study, we explored the risk factors for recurrence in patients with HCC who underwent curative resection. Moreover, we established a novel, effective, and valid equation for predicting the probability of recurrence and OS after curative resection. TNM stage and tumor size were integrated into the equation, and the Kaplan-Meier survival analysis showed that patients with HCC with higher equation values displayed worse outcomes. The etiology of HCC is variable and includes chronic virus infection, nonalcoholic liver disease, aflatoxin, and other complications. 18 Due to the increased incidence of 
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Zhang et al obesity in the Western countries and the chronic virus infections in Asia, the incidence of HCC has remained high. [19] [20] [21] Many studies have demonstrated the prognostic value of TNM stage, tumor burden, and impaired liver function (liver fibrosis, liver cirrhosis, and decompensated liver function) in HCC. [22] [23] [24] [25] [26] [27] Other studies have also reported that for HCC caused by chronic hepatitis B virus infection, many HBVrelated indicators, including hepatitis B virus DNA load, HBsAg, and antiviral treatment, also affect the prognosis of patients with HCC. 21, [28] [29] [30] [31] [32] [33] However, these prognostic indicators have limited value when used alone. How to combine data to improve prognostic value is a clinically practical issue. The CLIP score was the first system that took liver function and tumor characteristics into consideration for the classification of HCC treatment. However, the prognostic performance was reported to be poor because ~80% of the patients were classified with scores of 0-2. 34, 35 In this study, we combined TNM stage and tumor size into an equation. We have conducted a multivariable logistic regression analysis and included age, sex, HBsAg status, AFP level, Combining several markers into one equation allows an analysis of patients with HCC with more comprehensive information and provides individualized risk assessments. Similar to the results from a previous study, our results indicate that tumor size is an independent risk factor for recurrence in patients with HCC. 36 Tumor size is one of the most important tumor burden parameters. The results of this and previous studies indicate that advanced TNM stage closely associates with the development of HCC because of its positive correlation with tumor size and poor OS. 37, 38 Our equation exhibited superior discrimination of HCC recurrence in patients. Hence, the equation could be used to guide routine follow-up for patients. Especially, patients with HCC with high recurrence scores should undergo examinations more frequently, such as MRI or CT examinations, even if the most recent examination after curative resection indicates no cause for concern.
AFP and tumor multiplicity have been reported as prognostic markers in HCC. 39 AFP is a serum HCC marker that has been previously used to monitor HCC recurrence. However, AFP levels can also be elevated in some diseases, such as liver cirrhosis and female reproductive system tumors. 40, 41 Although high preoperative AFP levels are associated with poorer HCC outcomes, there is a certain proportion of patients with HCC with AFP levels that are within the upper limit of normal. 42 For those AFP-negative patients with HCC, AFP is not a suitable prognostic marker. In this study, patients with HCC with abnormal or normal AFP levels could be effectively stratified using this equation. Tumor multiplicity is another prognostic marker that has been reported in HCC. 43 According to this study, equation scores significantly differ between patients with a single HCC and those with multiple HCCs. No matter whether patients with HCC have a single tumor or multiple tumors, our equation can further risk stratify these subpopulations with HCC.
Whether or not the equation can improve the prognosis of patients with HCC remains an interesting and important question. The main reason why HCC is difficult to treat is its high recurrence rate. Moreover, the clinical symptoms of HCC are not obvious. When the typical symptoms occur, HCC has typically progressed to a state that makes treatment difficult. Therefore, the method for screening patients with HCC after surgery to facilitate early recurrence detection is a clinically critical problem. The early detection of HCC recurrence and early intervention can improve patient prognosis. However, high-frequency screening of all patients is not a cost-effective strategy. According to the results of this study, high-frequency follow-up and screening for high-risk patients, early detection of HCC recurrence, and early interventions may ultimately improve the prognosis of patients. However, this requires further prospective studies to confirm.
Conclusion
Here we established a novel and effective equation for predicting the probability of recurrence and OS after curative resection. Patients with a high recurrence score, based on this equation, should undergo additional high-end imaging examinations. Although our equation showed good performance, several limitations need to be addressed. First, the equation was derived from data collected at a single institution. Second, the etiology of HCC in China is mostly due to chronic hepatitis B. Third, because this study was a retrospective study, the results may be biased. For future performance algorithms, prospective cohort studies are needed.
